NCT00639262 2025-05-02
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Thomas Jefferson University
Phase 1 Completed
Clinical Trials
10 trialsNCT02298348 2025-02-17
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT01724606 2022-03-07
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00727233 2019-12-12
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00734526 2018-11-09
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01276210 2017-07-17
Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01518413 2015-02-27
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT00093613 2014-05-30
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn